What is the recommended management for a 70‑year‑old female with diabetes mellitus and chronic liver disease complicated by ascites, portal hypertension with varices, and hepatic encephalopathy?

Management of a 70-Year-Old Female with Diabetes Mellitus and Complicated Chronic Liver Disease

This patient requires immediate initiation of diuretic therapy for ascites (spironolactone 100 mg plus furosemide 40 mg daily), non-selective beta-blockers for variceal prophylaxis if not contraindicated, lactulose for hepatic encephalopathy, and urgent evaluation for liver transplantation eligibility. 1, 2, 3

Ascites Management

First-line therapy consists of sodium restriction to approximately 2 g/day combined with oral diuretics—spironolactone 100 mg plus furosemide 40 mg daily, titrated every 3–5 days as needed. 1, 4

• Combination aldosterone antagonist and loop diuretics are superior to sequential initiation, resolving ascites in 76% versus 56% of patients with lower rates of hyperkalemia (4% vs 18%). 5
• If >5 L paracentesis is performed, albumin (20% or 25% solution) should be infused at 8 g albumin/L of ascites removed to prevent post-paracentesis circulatory dysfunction. 1
• For refractory ascites unresponsive to maximum diuretic doses (spironolactone 400 mg and furosemide 160 mg daily), TIPSS should be considered. 1

Critical caveat: At age 70 with likely elevated MELD score given multiple complications, TIPSS requires extreme caution—age >70 years, serum bilirubin >50 μmol/L, platelet count <75×10⁹/L, MELD score ≥18, current hepatic encephalopathy, active infection, or hepatorenal syndrome are all relative contraindications. 1

Portal Hypertension and Variceal Management

Non-selective beta-blockers (carvedilol or propranolol) are indicated for primary prophylaxis of variceal bleeding and reduce the risk of decompensation or death (16% vs 27% over 3 years). 2, 5, 6

• Screening endoscopy must be performed immediately to assess for varices and classify them as small (F1) or large (F2/F3). 2
• For large varices or small varices with red wale marks, non-selective beta-blockers should be initiated with target heart rate reduction of 25% from baseline or to 55-60 bpm. 2, 7
• However, in this patient with refractory ascites, non-selective beta-blockers should be monitored closely, with dose reduction or discontinuation if hypotension or acute/progressive renal dysfunction develops. 1

For secondary prophylaxis (if prior variceal hemorrhage has occurred):

• Combination of non-selective beta-blockers plus endoscopic band ligation is first-line therapy. 2, 7
• In high-risk patients (Child-Pugh 10-13 or Child-Pugh 8-9 with active bleeding at endoscopy), pre-emptive TIPSS improves mortality and is standard of care. 8, 6

Hepatic Encephalopathy Management

Lactulose is first-line therapy, reducing mortality (8.5% vs 14%) and recurrent overt hepatic encephalopathy (25.5% vs 46.8%). 3, 5

• Lactulose should be titrated to achieve 2-3 soft bowel movements daily. 3
• Rifaximin 550 mg twice daily is second-line therapy and reduces recurrent hepatic encephalopathy when added to lactulose. 3, 5, 8
• Precipitating factors must be identified and treated: spontaneous bacterial peritonitis, gastrointestinal bleeding, electrolyte disturbances, constipation, infection, or medications (particularly benzodiazepines and opioids). 2, 3

Zinc supplementation is not routinely recommended for hepatic encephalopathy management. 3

Diabetes Management in Cirrhosis

Diabetes is an independent factor for poor prognosis in cirrhosis, associated with increased risk of ascites, renal dysfunction, hepatic encephalopathy, bacterial infections, and hepatocellular carcinoma. 9

• Metformin may have beneficial impact in chronic liver disease but is contraindicated in decompensated cirrhosis due to lactic acidosis risk. 9
• Insulin is often required in advanced cirrhosis and should be used cautiously with frequent glucose monitoring due to impaired hepatic gluconeogenesis and insulin clearance. 9
• Avoid sulfonylureas due to prolonged half-life and hypoglycemia risk in hepatic dysfunction. 9

Infection Prophylaxis

In patients with ascites and prior spontaneous bacterial peritonitis, secondary prophylaxis with norfloxacin reduces recurrence and hepatorenal syndrome risk. 10

• Diagnostic paracentesis should be performed for any clinical deterioration to rule out spontaneous bacterial peritonitis (ascitic fluid neutrophil count >250 cells/mm³). 4
• If spontaneous bacterial peritonitis is diagnosed with elevated creatinine, albumin 1.5 g/kg within 6 hours followed by 1 g/kg on day 3 is recommended. 1

Hepatorenal Syndrome Risk

This patient is at high risk for hepatorenal syndrome given multiple decompensating events; terlipressin combined with albumin is first-line treatment if it develops, improving reversal rates from 18% to 39%. 5, 8

Transplant Evaluation

All patients with cirrhosis and ascites should be evaluated for liver transplantation eligibility immediately. 4, 5

• At age 70, transplant candidacy depends on absence of significant comorbidities, adequate functional status, and center-specific age policies. 1
• Patients with refractory ascites not undergoing transplant evaluation should be offered palliative care referral. 1

Monitoring Strategy

• Endoscopic surveillance for varices at 1-2 year intervals in decompensated cirrhosis. 2
• Hepatocellular carcinoma surveillance with ultrasound ± AFP every 6 months. 5
• Regular assessment of MELD score to track disease progression and transplant priority. 11, 1
• Monitor for complications: renal function, electrolytes, complete blood count, and hepatic encephalopathy grade at each visit. 1, 3